Shattuck Labs, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Shattuck Labs, Inc. (STTK) on June 14, 2024. The filing serves as a Regulation FD disclosure regarding a press release issued on the same date. The company is an emerging growth company incorporated in Delaware.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial updates rather than financial performance.
Material Changes and Clinical Updates
The primary material event reported is the announcement of updated positive interim data from an ongoing Phase 1B dose expansion clinical trial. Key details include:
- Drug Candidate: SL-172154 administered with azacitidine.
- Indication: Frontline higher-risk myelodysplastic syndromes (MDS) and TP53 mutant acute myeloid leukemia (AML) patients.
- Status: Positive interim data reported as of June 14, 2024.
Guidance, Outlook, and Risks
The filing does not contain updated financial guidance, management commentary on future financial outlook, or specific risk factors beyond the standard disclaimer that the clinical data is not deemed "filed" for purposes of Section 18 of the Exchange Act. The press release containing the full data is attached as Exhibit 99.1.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release) for specific efficacy and safety data points regarding SL-172154.
- Verify the statistical significance and sample size of the interim data in the Phase 1B trial.
- Monitor upcoming regulatory filings for any changes to the company's cash burn rate or capital requirements resulting from trial progress.
- Confirm the timeline for potential Phase 2 trial initiation based on the interim results.